FY2020 Earnings Forecast for Incyte Co. Issued By Oppenheimer (INCY)

Incyte Co. (NASDAQ:INCY) – Stock analysts at Oppenheimer boosted their FY2020 earnings per share estimates for Incyte in a note issued to investors on Monday. Oppenheimer analyst J. Olson now expects that the biopharmaceutical company will earn $3.34 per share for the year, up from their previous estimate of $3.32. Oppenheimer has a “Hold” rating and a $110.00 price objective on the stock. Oppenheimer also issued estimates for Incyte’s FY2021 earnings at $5.21 EPS and FY2022 earnings at $7.77 EPS.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm had revenue of $381.50 million for the quarter, compared to analyst estimates of $360.34 million. During the same quarter in the prior year, the company posted $0.19 earnings per share. Incyte’s quarterly revenue was up 41.6% on a year-over-year basis.

INCY has been the topic of several other research reports. Raymond James Financial reissued a “buy” rating on shares of Incyte in a report on Tuesday, December 12th. Goldman Sachs Group assumed coverage on Incyte in a report on Friday, October 6th. They issued a “buy” rating and a $160.00 target price on the stock. Zacks Investment Research lowered Incyte from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. BidaskClub lowered Incyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Finally, ValuEngine lowered Incyte from a “hold” rating to a “sell” rating in a report on Wednesday, November 29th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $143.25.

Incyte (NASDAQ:INCY) traded up $0.55 during trading on Tuesday, reaching $94.63. The company’s stock had a trading volume of 1,410,000 shares, compared to its average volume of 1,660,000. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. The firm has a market capitalization of $19,970.00, a price-to-earnings ratio of -118.29 and a beta of 0.74. Incyte has a 12 month low of $88.81 and a 12 month high of $153.15.

In related news, insider David W. Gryska sold 6,760 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $98.87, for a total transaction of $668,361.20. Following the sale, the insider now owns 20,752 shares of the company’s stock, valued at $2,051,750.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Paul A. Friedman sold 28,507 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total value of $3,000,076.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 44,878 shares of company stock worth $4,636,494. Corporate insiders own 17.70% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Manning & Napier Advisors LLC purchased a new position in Incyte during the third quarter worth about $125,065,000. Janus Henderson Group PLC lifted its position in Incyte by 4,570.1% during the second quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock worth $131,622,000 after buying an additional 1,022,979 shares during the period. Old Mutual Global Investors UK Ltd. lifted its position in Incyte by 374.4% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 930,319 shares of the biopharmaceutical company’s stock worth $108,605,000 after buying an additional 734,235 shares during the period. Matrix Capital Management Company LP lifted its position in Incyte by 28.3% during the second quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock worth $226,225,000 after buying an additional 396,716 shares during the period. Finally, Jennison Associates LLC lifted its position in Incyte by 24.3% during the third quarter. Jennison Associates LLC now owns 1,633,173 shares of the biopharmaceutical company’s stock worth $190,657,000 after buying an additional 319,191 shares during the period. 90.75% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/23/fy2020-earnings-forecast-for-incyte-co-issued-by-oppenheimer-incy.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply